Flunisolide for the treatment of asthma

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 251-258

  Melani, Andrea S ^a  

^a Policlinico Le Scotte   (Italy)

Author keywords

Asthma; Flunisolide; Inhaled corticosteroid; Inhaler

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CICLESONIDE; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE; MOMETASONE FUROATE; AEROSOL; ANTIASTHMATIC AGENT; CORTICOSTEROID; FLUOCINOLONE ACETONIDE;

AEROSOL; ASTHMA; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RECEPTOR BINDING; HUMAN; INHALATION SPACER; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; NEBULIZER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; REVIEW; STEADY STATE; ADULT; ANALOGS AND DERIVATIVES; CHILD; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; EQUIPMENT DESIGN; FLUOCINOLONE ACETONIDE; HUMANS; INHALATION SPACERS;

EID: 84898900625     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.908117     Document Type: Review

References (46)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2012. Available from: www. ginasthma.org/uploads/ users/files/ GINA-Report-2012.pdf Last accessed 21 January 2014
2. National Heart Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the Diagnosis and Management of Asthma Full Report. 2007. Available from: www.nhlbi.nih.gov/ guidelines/asthma/ asthgdln.pdf Last accessed 21 January 2014
3. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma, A national clinical guideline 2012. Available from: www.sign.ac.uk/pdf/sign101.pdf Last accessed 21 January 2014
4. Lougheed DM; for the CTSACA. Canadian Thoracic Society 2012 Guideline update. diagnosis and management of asthma in preschoolers, children, and adults: executive summary. Can Respir J 2012:19(6):e81-8
5. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: ACCP/ ACAAI. Chest 2005;127(1):335-71
6. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105(6): 930-8
7. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006;100(6):1297-306
8. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159(9):941-55
9. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165(10):1377-83
10. Zeiger RS, Mauger D, Bacharier LB, et al. for the CARE Network of the National Heart, Lung, and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011;365:1990-2001
11. Papi A, Nicolini G, Baraldi E, et al. on behalf of the BEclomethasone and Salbutamol Treatment (BEST) for Children Study Group. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009;64:1463-71
12. Lavorini F, Corrigan CJ, Barnes PJ, et al. for the Aerosol Drug Management Improvement Team. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med 2011; 105(7):1099-103
13. Corren J, Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther 2003;25(3):776-98
14. US FDA. Available from: www.fda.gov/ Safety/MedWatch/SafetyInformation/ ucm368237.htm Last accessed 26 January 2014
15. Valeas. Available from: www.valeas.it/medic/ pro/Forbest.aspx Last accessed 24 January 2014
16. Tevaitalia. Available from: www.tevaitalia.it/ it/foglietto-illustrativo/ nisolid-monodose.htm Last accessed 24 January 2014
17. Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998;11384: 957-63
18. Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001;14(2): 197-208
19. van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013; 131(3):646-57
20. Scichilone N, Spatafora M, Battaglia S, et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy 2013;6:11-21
21. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-50
22. Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci 1996; 85(9):960-4
23. Nolting A, Sista S, Abramowitz W. Flunisolide HFA vs. flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm Drug Dispos 2001; 22(9):373-82
24. Nolting A, Abramowitz W. Multiple-dose proportionality study of flunisolide hydrofluoroalkane. Allergy Asthma Proc 2002;23(5):311-18
25. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001;87(5): 405-11
26. Bensch GW, Greos LS, Gawchik S, et al. Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2011;107(4):323-9
27. Gillman SA, Anolik R, Schenkel E, Newman K. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr (Phila) 2002;41(5):333-40
28. Kantar A, Mroueh S, Fiocchi A. A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. Allergy Asthma Proc 2007;28(6):671-87
29. Melani AS. Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respir Care 2012;57(7):1161-74
30. Camargo CA Jr, Ramachandran S, Ryskina KL, et al. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm 2007;64(10):1054-61
31. McLaughlin T, Leibman C, Patel P, Camargo CA Jr. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr Med Res Opin 2007; 23(6):1319-28
32. Marcus P, Oppenheimer EA, Patel PA, et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcome. Ann Allergy Asthma Immunol 2006;96(5):736-43
33. Hoegger P, Rohdewald P. Glucocorticoid receptors and fluticasone propionate. Rev Contemp Pharmacother 1998;9:501-22
34. O'Callaghan C, White J, Jackson J, et al. The output of flunisolide from different nebulisers. J Pharm Pharmacol 2002;54(4): 565-9
35. O'Callaghan C, White JA, Jackson JM, et al. Nebulisation of corticosteroids suspensions and solutions with a 2-agonist. J Pharm Pharmacol 2008;60(5):601-5
36. O'Callaghan C, White JA, Kantar A. Nebulization of corticosteroids to asthmatic children: large variation in dose inhaled. Respirology 2014;19(2):276-9
37. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003;112:58-63
38. Bergeron C, Hauber HP, Gotfried M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005;116(5):983-9
39. Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010 126(3): 511-18
40. Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbonbeclometasone: a real-world observational study. Clin Exp Allergy 2011;41(11): 1521-32
41. Colice G, Martin RJ, Israel E, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013;132(1):45-54
42. Rottier BL, Rubin BK. Asthma medication delivery: mists and myths. Paediatr Respir Rev 2013;14(2):112-18
43. Robinson CA, Tsourounis C. Inhaled corticosteroid metered-dose inhalers: how do variations in technique for solutions versus suspensions affect drug distribution? Ann Pharmacother 2013;47(3):416-20
44. ZuWallack RL, Rosen JP, Cohen L, et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J Allergy Clin Immuol 1997;99(3): 278-85
45. Kantar A, Carloni M, Kulkarni N, et al. Retention of flunisolide in rat lungs after single inhalation. Eur J Inflammation 2012; 10(1):127-31
46. Moore CD, Roberts JK, Orton CR, et al. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos 2013;41(2):379-89